Published in Law and Health Weekly, January 8th, 2005
This patent is important for the TTS project and includes the possibility to use TTS as combination therapy. This patent is the first in a series of applications related to combination of TTS and other established pharmaceuticals for cancer treatment.
The patent is valid until 2018.
The TTS patent portfolio in the U.S. consist of six separate patent families. With this new patent approval, three families are granted in the U.S. and the remaining are under review.
In Europe, Active Biotech has seven patent families...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly